QCG
TARO

Quadrant Capital Group’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Quadrant Capital Group’s Portfolio TARO Stock Details TARO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-687
Closed -$29.1K – 2786
2024
Q1 		$29.1K Sell
687
-53
-7% -$2.23K ﹤0.01% 1679
2023
Q4 		$30.9K Buy
740
+205
+38% +$7.56K ﹤0.01% 1622
2023
Q3 		$20.2K Buy
535
+3
+0.6% +$113 ﹤0.01% 1708
2023
Q2 		$20.2K Sell
532
-692
-57% -$21.7K ﹤0.01% 1712
2023
Q1 		$29.8K Buy
1,224
+706
+136% +$20.6K ﹤0.01% 1496
2022
Q4 		$15K Sell
518
-757
-59% -$22.5K ﹤0.01% 1781
2022
Q3 		$38K Buy
1,275
+774
+154% +$26.7K 0.01% 1200
2022
Q2 		$18K Buy
501
+394
+368% +$15K ﹤0.01% 1379
2022
Q1 		$5K Sell
107
-522
-83% -$24.4K ﹤0.01% 1946
2021
Q4 		$32K Buy
629
+493
+363% +$27.6K ﹤0.01% 1093
2021
Q3 		$9K Buy
136
+38
+39% +$2.63K ﹤0.01% 1669
2021
Q2 		$7K Hold
98
– – ﹤0.01% 1751
2021
Q1 		$7K Hold
98
– – ﹤0.01% 1682
2020
Q4 		$7K Buy
98
+38
+63% +$2.44K ﹤0.01% 1599
2020
Q3 		$3K Buy
+60
New +$3.73K ﹤0.01% 1768
2018
Q4 		– Sell
-56
Closed -$4K – 2320
2018
Q3 		$4K Hold
56
– – ﹤0.01% 1660
2018
Q2 		$5K Hold
56
– – ﹤0.01% 1586
2018
Q1 		$4K Sell
56
-137
-71% -$13.9K ﹤0.01% 1637
2017
Q4 		$17K Hold
193
– – 0.01% 981
2017
Q3 		$19K Sell
193
-265
-58% -$28.8K 0.01% 927
2017
Q2 		$46K Buy
458
+105
+30% +$11.9K 0.02% 583
2017
Q1 		$37K Buy
353
+171
+94% +$18.9K 0.02% 659
2016
Q4 		$16K Buy
182
+157
+628% +$16.4K 0.01% 848
2016
Q3 		$2K Sell
25
-7
-22% -$927 ﹤0.01% 1535
2016
Q2 		$2K Buy
32
+18
+129% +$2.55K ﹤0.01% 1497
2016
Q1 		$1K Buy
14
+3
+27% +$426 ﹤0.01% 1643
2015
Q4 		$1K Sell
11
-50
-82% -$7.3K ﹤0.01% 1489
2015
Q3 		$8K Hold
61
– – 0.01% 726
2015
Q2 		$8K Buy
+61
New +$8.7K 0.01% 757

Other funds holding TARO

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AIIMS
Analyst IMS Investment Management Services Tel-Aviv, Israel $3.3B AUM 20.27% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GCM
Gladius Capital Management Chicago, Illinois $2.24B AUM 23.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $10.6B AUM 19.99% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Carson Wealth (CWM LLC)
Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Quadrant Capital Group's TARO Position: Q2 2024 in Review

Quadrant Capital Group sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2024, closing a stake of 687 shares — an estimated $29.1K sold.

Quadrant Capital Group first reported a position in TARO in Q2 2015 and held it in 29 quarters. The position peaked at $46K in Q2 2017. 16 funds tracked by Wall St. Rank hold TARO as of Q2 2024.

  • Quadrant Capital Group reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 687 Taro Pharmaceutical Industries Ltd. shares in Q2 2024, an estimated $29.1K.
  • Quadrant Capital Group first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2015 and held it in 29 quarters.
  • Quadrant Capital Group's Taro Pharmaceutical Industries Ltd. position peaked at $46K in Q2 2017.
  • 16 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2024.

Based on Quadrant Capital Group's 13F filing for Q2 2024, filed 12 Aug 2024.